ES2357960T3 - Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos. - Google Patents

Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos. Download PDF

Info

Publication number
ES2357960T3
ES2357960T3 ES05076809T ES05076809T ES2357960T3 ES 2357960 T3 ES2357960 T3 ES 2357960T3 ES 05076809 T ES05076809 T ES 05076809T ES 05076809 T ES05076809 T ES 05076809T ES 2357960 T3 ES2357960 T3 ES 2357960T3
Authority
ES
Spain
Prior art keywords
cells
peptide
muc
cell
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05076809T
Other languages
English (en)
Spanish (es)
Inventor
Babita Agrawal
Mark J. Krantz
Mark A. Reddish
Michael B. Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seagen Inc
Original Assignee
Oncothyreon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncothyreon Inc filed Critical Oncothyreon Inc
Application granted granted Critical
Publication of ES2357960T3 publication Critical patent/ES2357960T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES05076809T 1997-05-08 1998-05-07 Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos. Expired - Lifetime ES2357960T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4594997P 1997-05-08 1997-05-08
US45949P 1997-05-08

Publications (1)

Publication Number Publication Date
ES2357960T3 true ES2357960T3 (es) 2011-05-04

Family

ID=21940709

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05076809T Expired - Lifetime ES2357960T3 (es) 1997-05-08 1998-05-07 Procedimiento para generar células t activadas y células presentadoras de antígenos pulsadas con antígenos.

Country Status (10)

Country Link
US (1) US6600012B1 (cg-RX-API-DMAC10.html)
EP (3) EP0986636B1 (cg-RX-API-DMAC10.html)
JP (1) JP4480800B2 (cg-RX-API-DMAC10.html)
AT (2) ATE394474T1 (cg-RX-API-DMAC10.html)
AU (1) AU727863B2 (cg-RX-API-DMAC10.html)
CA (1) CA2289742C (cg-RX-API-DMAC10.html)
DE (2) DE69839443D1 (cg-RX-API-DMAC10.html)
DK (1) DK1634949T3 (cg-RX-API-DMAC10.html)
ES (1) ES2357960T3 (cg-RX-API-DMAC10.html)
WO (1) WO1998050527A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19906744A1 (de) * 1999-02-18 2000-08-24 Martin Roecken Verfahren zur Herstellung antitumoraler Th1-Zellen
CA2368967A1 (en) * 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
GB9921337D0 (en) 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
ES2424131T3 (es) * 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US7282222B2 (en) 2002-03-15 2007-10-16 The United States Of America As Represented By The Department Of Veterans Affairs Methods and compositions for directing cells to target organs
EP1572918B1 (en) * 2002-04-15 2011-10-19 Oncothyreon Inc. Synthetic glyco-lipo-peptides as vaccines
US20060142546A1 (en) * 2002-09-05 2006-06-29 Franz-Georg Hanisch Immunogenic muc1 glycopeptides
CA2501527A1 (en) * 2002-10-10 2004-04-22 Catherine A. Phillips Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope
US20050045205A1 (en) * 2003-08-29 2005-03-03 Stach Steven R. Apparatus and method for cleaning printed circuit boards
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
JP5060134B2 (ja) * 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
WO2010002478A2 (en) 2008-07-03 2010-01-07 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
RU2377994C1 (ru) * 2008-05-21 2010-01-10 Леонид Валентинович Загребин Способ иммунореабилитации онкозаболеваний
US20100059084A1 (en) * 2008-09-10 2010-03-11 Austin American Technology Corporation Cleaning and testing ionic cleanliness of electronic assemblies
RU2578420C2 (ru) 2010-05-10 2016-03-27 Эсенд Байофармасьютикалз Пти Лтд Иммуностимулирующие и вакцинные композиции
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク. アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン
WO2013103658A1 (en) 2012-01-03 2013-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Native and agonist ctl epitopes of the muc1 tumor antigen
JP2016520073A (ja) 2013-05-14 2016-07-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung Muc−1リポペプチドによるワクチン免疫で肺癌を治療する方法
WO2015058831A1 (en) 2013-10-25 2015-04-30 Merck Patent Gmbh Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines
CN110325205B (zh) 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR20240005989A (ko) 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ, インコーポレイテッド 1型真性糖尿病(t1d)を治療するためのmhcクラスii t細胞調節多量体ポリペプチド及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135068T3 (es) 1994-06-13 1999-10-16 Unilever Nv Activacion de blanqueantes.
DK0765386T3 (en) * 1994-06-14 2015-01-26 Univ Leland Stanford Junior Methods for T cell activation in vivo with antigen-incubated dendritic cells
AU5849796A (en) * 1994-12-27 1996-08-07 United Biomedical Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics
AU6330896A (en) * 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
CA2282300C (en) 1997-02-24 2011-08-02 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Also Published As

Publication number Publication date
US6600012B1 (en) 2003-07-29
EP1634949B1 (en) 2010-12-15
CA2289742C (en) 2013-07-16
JP2001525668A (ja) 2001-12-11
JP4480800B2 (ja) 2010-06-16
EP0986636B1 (en) 2008-05-07
ATE394474T1 (de) 2008-05-15
AU7371298A (en) 1998-11-27
EP1634949A1 (en) 2006-03-15
DE69842060D1 (de) 2011-01-27
WO1998050527A1 (en) 1998-11-12
EP2341072A2 (en) 2011-07-06
CA2289742A1 (en) 1998-11-12
EP2341072A3 (en) 2013-10-30
AU727863B2 (en) 2001-01-04
DK1634949T3 (da) 2011-03-28
DE69839443D1 (de) 2008-06-19
EP0986636A1 (en) 2000-03-22
ATE491465T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
EP1634949B1 (en) Method for generating activated T-cells and antigen-pulsed antigen-presenting cells
TW514530B (en) Tumor vaccines and methods for their production
US8552145B2 (en) Vaccine for modulating between T1 and T2 immune responses
Agrawal et al. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes.
WO2021074389A1 (en) Immunogenic compounds for treatment of adrenal cancer
AU781376B2 (en) Telomerase-specific cancer vaccine
JP4592702B2 (ja) NY−ESO−1とアジュバントのinvivo有効性
AU2002309141A1 (en) Vaccine for modulating between T1 and T2 immune responses
US20020018806A1 (en) Lipopeptide adjuvants
US20210283237A1 (en) Vaccine compositions
EP1852126A2 (en) Vaccine for modulating between T1 and T2 immune responses
AU4111999A (en) Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes